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ofDiseases, TenthRevisionSummaryAlthough autopsy diagnosis includes routinely, a thorough evaluation of all available pathological
results and also of any available clinical data, the contribution of this clinical information to the diagnostic
yield of the autopsy has not been analyzed. We aimed to determine to which degree the use of clinical data
improves the diagnostic accuracy of the complete diagnostic autopsy (CDA) and the minimally invasive au-
topsy (MIA), a simplified pathological postmortem procedure designed for low-income sites. A total of 264
coupled MIA and CDA procedures (112 adults, 57 maternal deaths, 54 children, and 41 neonates) were per-
formed at the Maputo Hospital, Mozambique. We compared the diagnoses obtained by the MIA blind to
clinical data (MIAb), the MIA adding the clinical information (MIAc), and the CDA blind to clinical infor-
mation (CDAb), with the results of the gold standard, the CDA with clinical data, by comparing the
International Classification of Diseases, Tenth Revision codes and the main diagnostic classes obtained with
each evaluation strategy (MIAb, MIAc, CDAb, CDAc). The clinical data increased diagnostic coincidence
to the MIAb with the gold standard in 30 (11%) of 264 cases and modified the CDAb diagnosis in 20 (8%)
of 264 cases. The increase in concordance between MIAb and MIAc with the gold standard was significant
in neonatal deaths (κ increasing from 0.404 to 0.618, P = .0271), adult deaths (κ increasing from 0.732 to
0.813, P = .0221), and maternal deaths (κ increasing from 0.485 to 0.836, 0.;P b .0001). In conclusion,
the use of clinical information increases the precision ofMIA and CDA andmay strengthen the performance
of the MIA in resource-limited settings.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).0.485, respectively) and substantial for children and adults1. Introduction
The autopsy is the gold standard methodology for cause of
death investigation. It is also a valuable tool to maintain accu-
rate mortality statistics, which remain essential for public
health and health service planning. Unfortunately, autopsy
rates, which have markedly declined in Western countries in
the last decades, have always been very low in low-income
countries. Indeed, the feasibility of conducting autopsies in
these sites faces notable barriers including cultural and/or reli-
gious apprehension, which lead to a poor acceptability of the
conventional autopsy procedure [1,2]. The lack of infrastruc-
tures and the low number of trained pathologists are also a lim-
itation for a time-consuming examination such as complete
diagnostic autopsy (CDA). Finally, the fact that many deaths
occur outside the health system [3] results in a serious con-
straint for autopsy practice in low-income countries.
In the last few years, our group has developed and refined a
minimally invasive autopsy (MIA) method specifically de-
signed for low-resource sites as a feasible alternative to the
CDA. The procedure, which consists of sampling of fluids
and key organs using biopsy needle followed by histopatho-
logic and microbiological investigation of the obtained sam-
ples, can be rapidly performed by trained technicians close to
the place where death occurs and is more acceptable than the
CDA [4]. Thus, MIA can be relatively easily implemented as
a surveillance method in settings where cause of death infor-
mation is scarce and most needed [5].
This MIA procedure has recently been validated for neo-
nates, children, maternal deaths, and other adults from
Mozambique [6-9]. In these validation studies, the concor-
dance between the 2 procedures (MIA and CDA) has been
moderate for neonatal and maternal deaths (κ = 0.404 and(κ = 0.704 and 0.732, respectively). In all these previous stud-
ies, the MIA results have been analyzed blindly to any clinical
data in an attempt to determine the accuracy of the technique
per se. In contrast, in all these studies, the CDA diagnosis in-
cluded, as it is the rule in the routine activity of all departments
of pathology, not only a thorough evaluation of all available
macroscopic and microscopic and microbiological results,
but also any available clinical data [10].
The contribution of the clinical data to the diagnostic yield
of the MIA has not been analyzed. Interestingly, to our knowl-
edge, the degree to which the addition of the clinical data re-
sults in an increase in the diagnostic yield of the CDA has
not been evaluated either. Thus, the aim of this study is to de-
termine the contribution of adding the clinical information to
the microbiological and pathological results of the MIA in
the final attribution of cause of death. We have also evaluated
the contribution of the use of the clinical information to the ac-
curacy of the CDA. For this purpose, we have compared the
diagnoses obtained with the sole laboratory evaluation of the
samples acquired through theMIA and the CDAwith those di-
agnoses achieved after the addition of the clinical information
to the laboratory results.2. Materials and methods
2.1. Study setting and design
This observational study received the approval of the Clin-
ical Research Ethics Committee of the Hospital Clinic of Bar-
celona (Spain; File 2013/8677) and the National Bioethics
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13). The study was conducted at the Department of Pathology
of the Maputo Central Hospital, a 1500-bed government-
funded quaternary health care center, in collaboration with
the departments of obstetrics and gynecology, pediatrics, and
internal medicine.
Deaths of all ages (with the exception of neonates) having
occurred in the hospital premises from November 2013 to
March 2015 were eligible for recruitment if they fulfilled the
following criteria: (1) a CDA requested by the clinician as part
of the medical evaluation of the patient;, (2) a verbal informed
consent to perform the autopsy given by the relatives;, and (3)
no traumatic origin.
Coupled MIA and CDA procedures were performed in 264
cases. The study included 41 neonates (median age, 3 days;
range, 0-25 days), 54 children (median age, 4 years; range, 1
month–15 years), 57 maternal deaths (median age, 27 years;
range, 15-39 years), and 112 other adults (median age, 36
years; range, 15-76 years).
2.2. Autopsy procedures and laboratory analyses
Detailed pathological and microbiological methods of the
MIA have been described elsewhere [11,12]. All MIA proce-
dures aimed at obtaining samples of the blood, cerebrospinal
fluid, liver, lungs, bonemarrow, central nervous system, heart,
kidney, and spleen (and also the uterus and placenta, if avail-
able, in maternal deaths). We used a portable ultrasound
(US) scan device (Mindray Z6; Mindray Med Int Ltd, Shenz-
hen, China) to evaluate the liver, the spleen, the kidneys, and,
in women of childbearing age, the pelvis. Any lesions or ab-
normal fluid (ascites, pleural effusions) identified, as well as
the position of the spleen and the kidneys, were recorded. Af-
ter the US examination, the gel was removed, the areas of the
body to be punctured were cleaned and sterilized, and the sam-
ples were obtained without direct US guidance [11]. Samples
were obtained for microbiological and histologic analyses.
The body fluids were analyzed only with serologic and micro-
biological techniques. Within 30 minutes after completing the
MIA, the CDA procedure was performed by another patholo-
gist not involved with the MIA following a standardized pro-
tocol [10,13]. Histologic and microbiological analyses were
conducted from the same viscera collected in theMIA and also
from any gross lesions, when identified. No samples of the
body fluids (blood and cerebrospinal fluid) were obtained at
the CDA.
The histologic samples from the MIA were analyzed
blindly to any clinical information by a team of 2 pathologists
not involved with the CDA. Two microbiologists evaluated
the results of the microbiological analyses. Details of the ana-
lytical methodology have been described elsewhere [6-9]. The
microbiological analyses included both classic cultures and
molecular techniques.
After a washout period of 3 to 6 months, the same team of
experts analyzed the samples of the CDA following the same
approach used for the analysis of the MIA samples, but tissuesobtained during CDA were not cultured, and only molecular
methods were used to investigate pathogens. In the pathological
evaluation, the macroscopic data of the CDA were available to
the investigators, but the investigators were blind to the clinical
information.
2.3. Review of the clinical charts
Clinical information from all recruited patients was collected
using a standardized questionnaire. The same investigator
(Q. B.) was tasked with conducting the clinical data abstraction
of all cases after a thorough revision of the entire medical re-
cord. The data collection included, among others, retrieving
from the clinical process demographic data, medical history,
and information about the inpatient admission process and the
clinical information of the disease during hospitalization includ-
ing signs and symptoms, physical examination, laboratory re-
sults, imaging results, and treatment received. In maternal and
neonatal deaths, the obstetrical history was also included.
2.4. Determination of the cause of death blind to
clinical data
Once the analyses of theMIA samples had been completed,
a panel evaluated the pathological and microbiological reports
data of the MIA and assigned the diagnosis. This panel was
composed of a pathologist and a microbiologist, as well as a
pediatrician, an obstetrician, or a clinician with expertise in
epidemiology depending on the age group of the patients
evaluated in a session. In the first cause of death attribution
meeting, the MIA diagnosis was made in the absence of the
clinical information (“MIA blind,” ie, MIAb diagnosis).
Once the analyses of the CDA samples had been completed,
a different panel composed of a pathologist, a microbiologist,
and a clinician evaluated the pathological and microbiological
reports of the CDA and assigned the cause of death using the
samemethodology. Similarly, in this first cause of death attribu-
tionmeeting, the CDAdiagnosis wasmade in the absence of the
clinical information (“CDA blind,” ie, CDAb diagnosis).
2.5. Determination of the cause of death enhanced
with clinical data
Twelve to 18 months after the MIAb diagnosis was ob-
tained, a different panel with identical composition (1 patholo-
gist, 1 microbiologist, and 1 clinician) reviewed again theMIA
microbiological and histologic reports, this time with all avail-
able clinical data. Thus, a new MIA diagnosis enhanced with
clinical information (MIAc diagnosis) was assigned.
After a minimum washout period of 3 months (range, 3-6
months), the same panel involved in MIAb analysis also eval-
uated the data from the CDA and assigned the final CDA diag-
nosis of cause of death using the same methodology. This final
CDA diagnosis integrated all the findings from the autopsy
(macroscopic, histologic, and microbiological analyses) and
Table 1 Changes in ICD-10 cause of death diagnosis between the MIAb and the MIAc
















J12.1 Sepsis of newborn (no agent) P36.9 Sepsis of newborn
(streptococcus, group B)





P23.9 Intestinal occlusion P76.9 Intestinal occlusion P76.9 Intestinal occlusion P76.9
Unknown a R99 Kernicterus, unspecified P57.9 Kernicterus, unspecified P57.9 Kernicterus, unspecified P57.9
Respiratory syncytial
virus pneumonia b,c
J12.1 Severe birth asphyxia P21.0 Respiratory syncytial
virus pneumonia b
J12.1 Severe birth asphyxia P21.0
Neonatal sepsis
(Escherichia coli) c,d

































J14 Rabies A82 Pneumonia (H
influenza) b
J14 Rabies A82
Unknown c R99 Rabies A82 Tuberculosis b A15 Rabies A82
Pulmonary
hemorrhage e



















secondary to rupture of uterus
during labor
O71.1 Hemorrhagic shock
secondary to rupture of
uterus during labor
O71.1 Hemorrhagic shock







































Puerperal sepsis c,d O85 Hemorrhagic shock
secondary to premature
separation of placenta






A41.5 Hemorrhage due to premature
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Table 1 (continued)
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Unknown c R99 Hemorrhagic shock
secondary to premature
separation of placenta




Unknown c R99 Hemorrhagic shock
secondary to uterine atony
O45.9 Unknown R99 Hemorrhagic shock
secondary to uterine atony
O45.9
Adults
Unknown f R99 Hypertension I10 Cerebral hemorrhage I61 Cerebral hemorrhage I61
Unknown f R99 Hypertension I10 Cerebral hemorrhage I61 Cerebral hemorrhage I61
Cardiovascular dis-
ease, unspecified f,g































I51.6 Gastric ulcer with
hemorrhage
K25.0 Gastric ulcer with
hemorrhage
K25.0 Gastric ulcer with
hemorrhage
K25.0
Alcoholic cirrhosis a,b K70.2 Esophageal varices with
bleeding
I85.0 Esophageal varices with
bleeding





J15.3 Type 2 diabetes mellitus with
ketoacidosis
E11.1 Pulmonary edema g J81 Type 2 diabetes mellitus
with ketoacidosis
E11.1
Unknownc R99 Gastroenteritis of unspecified
origin
A09 Unknown R99 Gastroenteritis of
unspecified origin
A09
Unknown c R99 Gastroenteritis of unspecified
origin
A09 Unknown R99 Gastroenteritis of
unspecified origin
A09









I51.6 Cardiac arrest, sudden
cardiac death
I46
NOTE. For each case, the diagnosis of the CDAb and the gold standard (CDAc) are also included.
a Cases in which the clinical information resulted in an increased diagnostic accuracy betweenMIAb andMIAc with no changes in the diagnostic accuracy of
CDAb versus CDAc.
b Cases in which the diagnosis reached in the MIAb or CDAb was included as an associated condition in the final chain of events of the gold standard.
c Cases in which the addition of the clinical information resulted in an increased diagnostic accuracy between MIAb and MIAc and also in an increased
diagnostic accuracy between CDAb and CDAc.
d Cases in which theMIAb or the CDAb cause of death was considered to be a misdiagnosis due to an overinterpretation of microbiological and/or histologic
findings with a low level of evidence.
e Cases in which the addition of the clinical information resulted in no change betweenMIAb andMIAc diagnosis, but it resulted in a change between CDAb
and CDAc.
f Cases in which the addition of clinical data to the MIAb (MIAb to MIAc) did not result in an increased diagnostic accuracy.
g Cases in which the gold standard diagnosis was a refinement of the MIAb or CDAb diagnosis.
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189Contribution of clinical data to MIAthe clinical information (CDAc diagnosis) and was considered
the gold standard for cause of death attribution.
2.6. Cause of death coding and diagnostic grouping,
definition of concordance and coincidence in diagno-
sis, and definition of change in diagnosis
All morbid conditions identified in the MIAb, the MIAc,
the CDAb, or the CDAc, directly leading to death and any un-
derlying conditions (if present), as well as any other significant
conditions possibly contributing to death, were codified fol-
lowing the International Classification of Diseases, Tenth Re-
vision (ICD-10). This codification process was conducted
independently for the MIAb, MIAc, CDAb, and CDAc. Al-
though all diseases included in the chain of events leading to
death (underlying conditions) as well as any significant condi-
tions possibly contributing to death were evaluated, only the fi-
nal cause of death, that is, the disease directly leading to death,
was analyzed to compare the methods.
Diagnoses were grouped into broad classes, specifically
defined for each study group [6-9]. Neonatal deaths were
classified into 6 classes (infectious diseases, intrapartum com-
plications, preterm complications, congenital malformations,
other conditions, and nonconclusive). Pediatric deaths were
classified into 5 classes (infectious diseases, malignant tumors,
congenital malformations, other diseases, and nonconclusive);
adult deaths, 4 classes (infectious diseases, malignant tumors,
other diseases, and nonconclusive); and maternal deaths, 6
classes (pregnancies with abortive outcome, hypertensive dis-
orders, obstetric hemorrhage, pregnancy-related infections,
nonobstetric complications, and unexplained deaths). The di-
agnostic concordance between 2 methods was determined by
comparing the diagnostic classes. The diagnoses were consid-
ered as concordant when they were in the same diagnostic
class.
The diagnostic coincidence between 2 methods was deter-
mined by comparing the ICD-10 codes. The ICD-10 system
classifies diagnoses into nested categories of different hierar-
chical levels, where diseases or conditions are organized in
chapters, blocks, and 3 character categories [14]. The diagno-
ses obtained with 2 methods were considered as coincident
when they were identical in chapter and block.
Any variation in terms of block between 2 methods was
considered as a change in diagnosis. Any case in which the ad-
dition of clinical data caused a change in the ICD-10 coding
resulting in a coincidence in terms of the ICD-10 block with
the gold standard was considered an increase in diagnostic
accuracy.2.7. Statistical methods
The concordance between the diagnostic categories ob-
tained in the MIAb, MIAc, and CDAb with the gold standard
(CDAc) was evaluated by means of the κ coefficient, which
was interpreted as suggested by Landis and Koch [15]. Thedifferences between the 2 κ values (MIAb versus CDAc and
MIAc versus CDAc) were assessed based on Student t distri-
bution of 1000 bootstrap replications of paired differences
for comparing correlated κ coefficients [16]. The change in
the proportion of cases with an identifiable cause of death
(both by MIA and CDA) and in the overall agreement of the
MIA with the gold standard when clinical information was
added was assessed using the McNemar exact test. The statis-
tical analyses were performed using Stata version 14.1 (Stata,
College Station, TX) [17].3. Results
3.1. Cause of death determination using MIA and CDA
methods
A cause of death was identified in the MIAb in 235 (89%)
of 264 cases, whereas in 29 cases (11%), no conclusive diag-
nosis was reached. After adding the clinical data, a cause of
death was defined in the MIAc in 246 (93%) of 264 cases.
A cause of death was identified in the CDAb in 257 (97%)
of 264 cases, whereas in 7 cases (3%), no conclusive diagnosis
was reached. After adding the clinical data, a cause of death
was identified in the CDAc in 263 (99%) of 264, and only 1
case remained as nonconclusive.
3.2. Concordance in disease groupingwith the gold standard
The overall concordance of the MIAc with the gold standard
regarding identical diagnostic class increased from 80% (212/
264) to 89% (235/264; P b .001). The overall concordance of
the CDAb with the gold standard was 250 (95%) of 264.
In neonatal deaths, the agreement in disease grouping be-
tween the MIAb and the gold standard was 68% (28/41 cases;
κ value = 0.404, moderate agreement) and increased to 78%
(32/41 cases; κ value = 0.618, substantial agreement) when in-
cluding the clinical data in the MIA (comparison MIAc versus
gold standard). The increase of κ value was statistically signif-
icant in this age group (P = .027).
In children, the agreement in disease grouping between the
MIAb and the gold standard was 89% (48/54 cases; κ value =
0.704, substantial agreement), which increased to 93% (50/54
cases; κ value = 0.802, almost perfect agreement) in the com-
parison between MIAc and the gold standard. This increase of
κ value did not reach statistical significance (P = .160).
In maternal deaths, the agreement in disease grouping
between the MIAb and the gold standard was 68% (39/57
cases; κ value = 0.485, moderate agreement) compared with
the gold standard. This value increased to 89% (51/57 cases;
κ value = 0.836, almost perfect agreement) in the comparison
between MIAc and the gold standard. The increase of κ value
was statistically significant in this group ( 0.;P b .001).
In the adult group, the agreement in disease grouping be-
tween MIAb and the gold standard was 87% (97/112 cases;
Table 2 The most informative clinical data, resulting in significant changes of the MIAb to clinical data diagnoses
Clinical symptom No. of cases
Evidence of bleeding 12
Evidence of an underlying chronic condition (eg, hypertension and diabetes) 7
Evidence of gastrointestinal disease (eg, vomiting, diarrhea, and abdominal pain) 5
Evidence of a premortem injury (eg, animal bites) 4
Evidence of a congenital disease (eg, hemoglobinopathies) 1
Recent treatments (eg, antimalarials) 1
190 F. Fernandes et al.κ value = 0.732, substantial agreement), which increased to
91% (102/112 cases; κ value = 0.813, almost perfect agree-
ment) in the comparison between MIAc and the gold standard.
The increase of κ value was again statistically significant in
this group (P = .022).
3.3. Changes in diagnostic coincidence related to the
addition of clinical data
Overall, the addition of clinical data resulted in a change in
the MIAb diagnosis in 35 of 264 cases; in 30 of them, the
change resulted in a better coincidence with the gold standard
diagnosis (increase in the diagnostic accuracy). Thus, the over-
all coincidence of the MIAb with the gold standard regarding
identical diagnostic block was 155 (59%) of 264 and increased
to 70% (185/264) for theMIAc diagnosis (P = .008). The over-
all coincidence of the CDAb with the gold standard was 244
(92%) of 264. The addition of clinical data significantly mod-
ified the CDAb diagnosis in 20 (8%) of 264 cases. In 17 of
them, theMIAb toMIAc diagnoses had also changed, whereas
in 3 cases, the clinical information had not resulted in a change
in the MIAb diagnosis. Table 1 shows detailed information of
the cases in which the addition of clinical information resulted
in a change in diagnosis (ICD-10 block) between the MIAb
and the MIAc and/or between the CDAb and the CDAc (the
gold standard).
In neonates, the addition of clinical information resulted in a
change in diagnosis from the MIAb to the MIAc in 5 (12%) of
41 cases. All 5 changes resulted in an increased coincidence with
the gold standard diagnosis. In 2 of these cases, the improved co-
incidence with the gold standard diagnosis was also observed af-
ter the addition of clinical data to the CDAb diagnosis.
In the pediatric group, a change in diagnosis fromMIAb to
MIAc occurred in 5 (9%) of 54 cases. Four of the 5 changes
resulted in an increased coincidence with the gold standard di-
agnosis. One case was a tetanus diagnosed as pneumonia in
the MIAb (the patient indeed had a pneumonia, which was
considered as a concomitant cause of death), and 2 cases were
rabies infections missed in the MIAb. In both cases, the virus
was successfully identified in the MIA by polymerase chain
reaction (PCR) techniques when the clinical information be-
came available and the Central Nervous System (CNS) sam-
ples were secondarily tested. The fourth case was a
hereditary factor VIII deficiency clinically diagnosed and
missed in the MIAb. Interestingly, in all 4 cases, the additionof clinical data to CDAb resulted in an increased coincidence
with the gold standard diagnosis.
In maternal deaths, the addition of clinical information resulted
in a change in diagnosis from MIAb to MIAc in 12 (21%) of 57
cases. All changes resulted in an increased coincidence with the
gold standard diagnosis. Eleven of the 12 changes in diagnosiswere
obstetric hemorrhages missed in the MIAb. In 7 of these 12 cases,
there was also an increase in accuracy in the CDAb diagnosis.
Finally, in adult deaths, a change in diagnosis from MIAb to
MIAc was observed in 13 (12%) of 112 cases. Nine of the 13
changes resulted in an increased coincidence with the gold stan-
dard diagnosis. In this group, changes occurred mostly in meta-
bolic conditions (diabetes mellitus) and gastrointestinal
disorders. There was another case of rabies, identified also by
PCR techniques in the MIA Central Nervous System (CNS)
samples once the clinical information triggered the testing. The
addition of clinical information resulted in diagnostic accuracy
increase of the CDA in 4 of these 13 cases.
3.4. Relevant clinical information
Table 2 shows the clinical data that were more informative,
resulting in significant changes of the MIAb diagnoses. Evi-
dence of bleeding, underlying chronic conditions, symptoms
of gastrointestinal disease, and previous history of accidents
or animal bites were particularly instructive.4. Discussion
This is, to our knowledge, the first study analyzing the con-
tribution of the clinical information to the diagnostic perfor-
mance of pathologic autopsy methods, namely, the MIA and
the CDA, in cause of death determination. Our results show
that, although the MIA and the CDA performed and analyzed
blindly to any clinical data have a good correlation with the
gold standard, the addition of clinical information to the path-
ological and microbiological findings results in a minor but
significant increase in the concordance in the diagnostic group
and in higher coincidence (identical ICD-10 coding in terms of
block) between the MIA and the CDA with the gold standard
diagnosis (CDA with clinical data). Overall, the addition of
clinical data modified the MIAb diagnosis in 35 cases, and
in 30 of them (12%), the change resulted in an increased
191Contribution of clinical data to MIAcoincidence with the gold standard diagnosis. As a result, the
accuracy of the MIA increased from 63% in the MIA blind
to clinical information (MIAb) to 76% in the MIA enhanced
with clinical information (MIAc).
We have previously reported the validation of the MIA
method when compared with the CDA, the gold standard for
cause of death attribution [6-9]. In these studies, we have used
a purist approach to specifically determine the validity of the
MIA procedure on its own, avoiding the use of clinical infor-
mation to reach the putativeMIA cause of death. The rationale
for this was to understand the potential usefulness of the meth-
odology by itself in case it would be applied in sites with min-
imal or no clinical information available, or at the community
level for deaths having occurred in the absence of any contact
with the health system. However, the diagnosis of clinical
autopsies, since first introduced by the Italian anatomist
Giovanni Battista Morgagni more than 250 years ago [18],
has traditionally relied on complementing the pathologic ob-
servations, initially macroscopic, and after Rudolf Virchow's
contributions, also microscopic [19], with any available clini-
cal data. The final diagnosis of a CDA in all pathology depart-
ments is based in the precise correlation between the
anatomical and pathological findings of the postmortem exam-
ination with the premortem clinical information from the pa-
tient [18,20,21]. Our study shows that the addition of clinical
data allowed for obtaining a diagnosis in 6 cases diagnosed as
nonconclusive in the CDAb and that this clinicopathological
correlation was needed to reach an adequate diagnosis in the
CDA in 20 additional cases (8%). Although it may be obvious
to accept that the clinical data improve any autopsy results, no
studies have evaluated to what extent the contribution of the
clinical data is key in the cause of death assignment process.
The present study included different age groups and a wide
variety of underlying diseases and syndromes, representative
of the wide spectrum of patients attended at a quaternary health
care center in a country like Mozambique, and thus, it allows
evaluating separately the contribution of this information in
all these groups. The improved diagnostic concordance from
MIAb to MIAc was particularly high in maternal deaths (κ
value increasing from moderate to almost perfect agreement,
0.;P b .001). Obstetric hemorrhage as a main cause of death
was missed in 11 cases in the MIAb (all but 1 case), but was
easily identified in the clinical records and, consequently,
was correctly diagnosed in the MIA enhanced with clinical
data. Interestingly, obstetric hemorrhage was also missed in
7 cases in the CDAb, as no signs of hemorrhage were detected
in the autopsy. Because obstetric hemorrhage is a condition
easily captured not only in the clinical records but even
through a simple interview such as the one conducted in the
verbal autopsy [22-24], our findings indicate that some degree
of obstetric information from the clinical records or the verbal
autopsy could significantly improve the diagnosis established
by the MIA in maternal deaths. The autopsy in women with
obstetric hemorrhage has a very limited contribution. How-
ever, it may help to exclude other causes of death or other con-
ditions that could have contributed to death, as shown in aprevious study conducted by our group in which eclampsia
was clinically missed in a patient [25].
In adult deaths, the diagnostic concordance with the gold
standard was significantly better with MIAc than with MIAb
(κ value increasing from substantial agreement in the MIAb
to almost perfect agreement in the MIAc, P = .021). With
the exception of a case of rabies, most of the diseases not
diagnosed in the blind MIA and captured in the clinically en-
hanced MIA were noninfectious in nature, including cardio-
vascular, metabolic, and gastrointestinal diseases. Diagnosis
of such entities, however, remains challenging even with the
classical CDA because of the variety of lesions and organs in-
volved. These cases often require a combination of all the
available macroscopic data and frequently of the clinical infor-
mation [26-28].
The increase in diagnostic concordance from MIAb to
MIAc compared with the gold standard was also evident in
children, although it did not reach statistical significance.
However, the analysis of the cases not diagnosed by the MIAb
provided relevant information. Two deaths were secondary to
rabies, which was successfully identified by PCR techniques
when the clinical data became available and the central ner-
vous system samples were retrospectively tested and conse-
quently correctly diagnosed in the clinically enhanced MIA.
Another case was a tetanus misdiagnosed in the blind MIA
and correctly diagnosed when the clinical information was
available. Again, both rabies and tetanus are conditions that
may easily be captured by the clinical history or, in its absence,
by a minimum narrative of the signs, symptoms, or events pre-
ceding death [29,30], and consequently, the information ob-
tained through these sources could significantly improve the
results of the MIA. Conditions arising from the bites or en-
counters with insects or animals, or related to intoxications,
poisoning, or exposures to other toxins or drugs (including tra-
ditional medicines) may present with unspecific systemic
changes and thus be difficult to diagnose through the blind ob-
servation of tissue samples obtained through the MIA. How-
ever, these conditions can easily be suspected or confirmed if
the right clues are provided by the clinical or the Verbal Au-
topsy (VA) interview. Interestingly, in all pediatric cases in
which the clinical information contributed to improve the
MIA diagnosis, this information was also relevant to amend
the CDAb diagnosis.
Finally, in neonates, the improved diagnostic concordance
from the MIAb to the MIAc was also significant (κ value in-
creasing frommoderate to substantial agreement,P = .021), al-
though the range of diseases not diagnosed in the MIAb and
captured in the clinically enhanced MIA was quite broad and
hinders reaching reliable conclusions.
In conclusion, our study indicates that, although the MIA
and the CDA blind to any clinical data have a good correlation
with the gold standard, the addition of clinical data has a minor
but significant impact on this correlation, increasing the diag-
nostic accuracy of the MIAb and CDAb in 12% and 8% of
the cases, respectively. Consequently, the use of clinical data
increases the diagnostic precision of the MIA, helping to
192 F. Fernandes et al.provide more robust data for cause of death surveillance in
resource-limited settings and its collection should therefore
be highly encouraged.Acknowledgments
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